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ABSTRACT 
Backglound: Recently, depression with Lewy body pathology before the 
appearance of parkinsonism and cognitive dysfunction has been drawing 
attention. Low cardiac metaiodobenzylguanidine (MIBG) uptake is helpful 
for early differentiation of Lewy body disease (LBD) from late-onset 
psychiatric disorders even before parkinsonism or dementia appears. In this 
study, we used MIBG uptake as a tool in suspected LBD, and evaluated the 
relationship of MIBG results to clinical characteristics and depressive 
symptoms. 
Methods: Fifty-two elderly inpatients with depression were included in 
this study. The Hamilton Depression Rating Scale (HDRS) was 
administered at admission, and 123I-MIBG cardiac scintigraphy was 
performed. Of 52 patients, 38 had normal and 14 had reduced MIBG 
uptake.  
Results: Correlation analyses of the late phase heart-to-mediastinum (H/M) 
ratio on the MIBG test and each item of the HDRS revealed that the H/M 
ratio was significantly correlated with scores of “agitation”, “anxiety-
somatic”, and “retardation” on the HDRS. Mean HDRS composite scores 
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of “somatic and psychic anxiety (Marcos)” and “somatic 
anxiety/somatization factor (Pancheri)” were higher in the low uptake 
group than in the normal uptake group. 
Conclusion: Elderly patients with depression who manifested an obvious 
somatic anxiety tend to show low MIBG uptake, and are more likely to 
have Lewy body pathology. 
       
Key words 
depression, elderly, metaiodobenzylguanidine, Lewy body disease, somatic 
anxiety 
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INTRODUCTION 
A close relationship of Lewy body disease (LBD) with depression has been 
repeatedly reported,1-3 and major depression occurs in around one-fourth to 
one-third of patients with Parkinson disease (PD).1,4 Dementia with Lewy 
bodies (DLB) produces more depressive signs than Alzheimer’s disease 
(AD),2 and the coexistence of major depression is also more frequent in 
DLB than in AD.3 Mild cognitive impairment (MCI) with LBD is 
associated with neuropsychiatric symptoms including depression, similar to 
those established for DLB.5 
   Recently, early non-motor, non-cognitive symptoms associated with 
LBD, such as REM sleep behavior disorder (RBD), olfactory dysfunction, 
autonomic dysfunction, and depression, have become very frequently 
reported.6,7 RBD, olfactory dysfunction, autonomic dysfunction, and 
depression often appear before parkinsonism or cognitive dysfunction 
become obvious.1,8 In the field of geriatric psychiatry especially, depression 
with Lewy body pathology before the appearance of parkinsonism and 
cognitive dysfunction has been drawing attention.8-10 Using low 
metaiodobenzylguanidine (MIBG) uptake as an indicator of LBD, late 
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onset depression without DLB criteria was reported to be one of the early 
manifestations of LBD.11 Further, the concept of a “pure psychiatric 
presentation (PPP) of LBD” was proposed, and the typical presentation of 
PPP was reported to be depression with elderly onset.9 Therefore, the 
clinical importance of Lewy body-related mental symptoms in patients 
without dementia and parkinsonism is strongly suggested.8 
   Although the importance of depression in LBD has been repeatedly 
emphasized, there have been relatively few reports on the frequency of 
LBD in aged patients with depression.12 It is not easy to infer Lewy body 
pathology before dementia or parkinsonism emerge. However, recently it 
was reported that a low cardiac MIBG uptake, but not a decreasing binding 
ratio on a dopamine transporter single photon emission computed 
tomography (DAT-SPECT), was helpful for early differential diagnosis of 
LBD from late-onset psychiatric disorders, even before parkinsonism or 
dementia appear.13 In another study, it was reported that low cardiac MIBG 
uptake is detected before the diagnosis of probable DLB.14 The high 
specificity of MIBG to detect LBD was repeatedly reported.15 Therefore, in 
this study, we used MIBG scintigraphy as a tool to identify suspected LBD 
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in patients, and evaluated the relationship of MIBG results to clinical 
characteristics and depressive symptoms. 
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METHODS 
Ethics 
This study was approved by the Internal Ethical Committee of the 
Okayama University Graduate School of Medicine, Dentistry, and 
Pharmaceutical Sciences (1506-006). After a complete description of the 
study to the subjects and their relatives, written informed consent was 
obtained. 
 
Subjects 
Eighty-three elderly patients with major depression (≥ 60 years old) entered 
the psychiatric ward of Okayama University Hospital between June 2010 
and January 2018. Of the 83 patients, 52 fulfilled the following inclusion 
and exclusion criteria. They all (1) were 60 years old or over, (ii) fulfilled 
the F32 or F33 codes of the International Classification of Diseases-10 
(ICD-10) criteria, (iii) had not experienced a manic or hypomanic episode; 
(iv) underwent 123I-MIBG myocardial scintigraphy as well as magnetic 
resonance imaging (MRI) or computed tomography (CT) of the head, and 
(v) received a Hamilton depression rating scale (HDRS) score. 
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   We excluded patients who met the following exclusion criteria for 123I-
MIBG scintigraphy: (i) taking tricyclic antidepressants, reserpine, and/or 
norepinephrine reuptake inhibitor, (ii) cardiac failure, (iii) ischemic heart 
disease that developed within six months of participation, (iv) poorly 
controlled diabetes mellitus (HbA1c >7.0%) or receiving insulin therapy, 
(v) severe kidney dysfunction or receiving hemodialysis, and (vi) a history 
of neoplasm within five years of participation.15 
   Other exclusion criteria were: (i) diagnosis of dementia or Parkinson 
disease at and before hospitalization, (ii) Huntington disease, normal 
pressure hydrocephalus, progressive supranuclear palsy, epilepsy, subdural 
hematoma, multiple sclerosis, or head injury with aftereffect, (iii) infection 
or focal regions revealed by MRI such as cerebral infarction or brain tumor 
that affects cognitive function, (iv) use of a cardiac pacemaker, aneurysm 
clips, prosthetic valves, cochlear implants, or other metal implants, (v) a 
history of alcohol or drug abuse, deficiency of vitamin B12 or folic acid, 
syphilis, or thyroid dysfunction, (vi) patients judged by a chief clinician to 
be inappropriate due to severe physical illness, and (vii) patients receiving 
drugs causing depression (steroids, α-methyl-dopa, clonidine, tamoxifen, 
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and cimetidine).15 
   Of 52 depressive patients, 38 patients with a normal MIBG uptake 
(heart-to-mediastinum (H/M) ratio ≥2.0 in the late image) were classified 
as the normal uptake group, and 14 patients with reduced MIBG uptake 
(H/M ratio <2.0 in the late image) were classified as the low uptake 
group.16  
 
Hamilton Depression Rating Scale (HDRS) and Global Assessment of 
Functioning Scale (GAF) 
The HDRS was originally published in 1960.17 It is a standard measure of 
depression severity, with 17 items that evaluate behavioral, physical, and 
mental symptoms of depression. The HDRS was rated by the chief 
psychiatrist of the patient at admission. 
Several studies reported factor analyses of the HDRS. Marcos and 
Salamero performed a factor analysis of the HDRS in aged people, and 
they extracted three factors.18 The factors were (1) inhibition and 
melancholic depression (items 1, 7, 8, 10, 14), (2) insomnia (items 4, 5, 6), 
and (3) somatic and psychic anxiety (items 11, 12, 13, 15). Pancheri et al. 
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performed a factor study of the HDRS in unipolar depressed outpatients 
and identified four factors: (1) somatic anxiety/somatization (items 4, 5, 6, 
11, 13, 15), (2) a psychic anxiety dimension (items 2, 9, 10, 17), (3) a pure 
depressive dimension (items 1, 7, 8), and (4) an anorexia factor (items 12, 
16).19 The total sums of all items in each factor were taken as the score of 
the factor.  
   The overall level of functioning was evaluated with the GAF.20 The 
scale values range from 1, which represents the hypothetically sickest 
individual, to 100, which represents the hypothetically healthiest. The GAF 
was scored by the chief clinician at both admission and discharge.  
 
Evaluation of clinical information 
Age, age at onset, sex, height, weight, and years of education were obtained 
from the medical records. Suspected parkinsonism at admission, visual 
hallucination, fluctuation of cognition, and RBD were evaluated using 
inpatient charts and nursing records by investigators who were blind to the 
MIBG uptake. Diagnoses of Parkinson disease and dementia at discharge 
were taken from the medical records. The antidepressants used at the time 
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of MIBG cardiac scintigraphy were obtained from the medical records. 
 
123I-MIBG cardiac scintigraphy and image analysis 
Cardiac planar images were acquired 15 min (early image) and 4 h (late 
image) after intravenous injection of 111 MBq of 123I-MIBG (FUJIFILM 
RI Pharma Co., Ltd., Tokyo, Japan) using a triple-head gamma camera 
equipped with a parallel-hole low-energy high-resolution collimator 
(GCA9300A/DI; Toshiba, Tokyo, Japan) before March 2014 (n= 27). After 
March 2014, we used a dual-head hybrid SPECT/CT system (Discovery 
NM/CT670 Pro, GE Healthcare, Chicago, IL, USA) equipped with an 
extended low energy general purpose (ELEGP) collimator and diagnostic 
multi-detector spiral CT (n= 25).  
The cardiac uptake of MIBG was determined by setting a region of 
interest (ROI) in the left cardiac ventricle and upper mediastinum using a 
semi-automatic ROI setting software program.21 The average counts per 
pixel in the H and M were determined within each ROI to calculate the H/M 
ratio at 15 min (early image) and 4 h (late image). The MIBG wash-out rate 
was calculated as follows:  
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(early H – early M) – (late H – late M) / K / (early H – early M) 
where K represents the decay correction factor. 
 
Head MRI 
Of the 52 elderly depressive patients, 51 subjects underwent T1-weighted, 
T2-weighted, and fluid-attenuated inversion recovery (FLAIR) MRI with a 
3-T scanner (Siemens, Erlangen, Germany) at the Okayama University 
Hospital during their hospitalization. Periventricular hyperintensities 
(PVH), and deep and subcortical white matter hyperintensities (DSWMH) 
were defined as hyperintensity areas on T2 and FLAIR images without any 
abnormality on T1 images in patients without neurological signs and/or 
symptoms.22 PVH and DSWMH were evaluated as five grades from 0 to 4 
using the grading scale released by the Japanese Brain Dock Society 
(http://jbds.jp/guideline.html) outlined by two reports.23,24 All images were 
read and assessed by two investigators who were blind to the MIBG uptake 
results.  
 
Statistical analysis 
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Statistical analysis was performed using the SPSS 23.0 software program 
(SPSS Inc., Chicago, IL, USA). Comparisons of continuous variables 
between the two independent groups were performed by independent 
sample t-tests. Comparison between proportions of two independent groups 
was calculated using Fisher’s exact test (2x2 table). Correlation between 
the H/M ratio of late-phase MBG and HDRS scores was evaluated by 
Spearman’s correlation coefficient. A value of p<0.05 was accepted as 
significant. 
   Comparisons of the scores of HDRS items between two independent 
groups were performed by Mann-Whitney’s U test. Among the synthetic 
factor scores of the HDRS, a test for normality (Shapiro-Wilk test) did not 
reject the hypotheses of normal distribution of the factor scores in 
“inhibition and melancholic depression” and “somatic and psychic anxiety” 
of the study of Marcos and Salamero, and “somatic anxiety/somatization 
factor” and “a psychic anxiety dimension” of the study of Pancheri et 
al.18,19 Therefore, comparison of those factor scores of the two groups was 
performed using a t-test, and other factor scores of the two groups were 
compared using Mann-Whitney’s U test.  
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RESULTS 
Sex, age, years of education, core features of DLB, and antidepressants 
No significant differences were found between the low and normal uptake 
groups with respect to sex, age, years of education, height, or weight (Table 
1). 
   Parkinsonism was suspected at the time of admission in 15 cases, but 
only 4 cases were diagnosed as Parkinson's disease at discharge, and others 
were diagnosed as parkinsonism due to antipsychotic drugs or psychiatric 
symptoms. Suspected parkinsonism at admission (p=0.013) and diagnosed 
Parkinson disease at discharge were more frequently observed in the low 
uptake group than in the normal uptake group (p=0.004). No significant 
differences were found between the low and normal uptake groups in the 
frequency of visual hallucination (p=0.069), fluctuation of cognition (p= 
0.470), RBD (p=0.269), dementia diagnosis at discharge (p=0.291) and 
calcium channel blockers (p=0.659). No significant differences were found 
as to the type of antidepressants between low and normal uptake groups 
(Table 1).  
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Neuroimaging findings 
The mean H/M ratio of early to late phases of MIBG uptake in the low 
uptake group was significantly lower than that in the normal uptake group, 
and the MIBG wash-out rate in the lower uptake group was significantly 
higher than that in the normal uptake group (Table 1).  
   No significant differences were found between the low and normal 
uptake groups with respect to PVH grade scores or DSWMH grade scores 
of head MRI (Table 1). 
 
HDRS scores and GAF scores 
Spearman’s correlation analysis between the H/M ratio of the late phase 
and each item of the HDRS revealed that the H/M ratio was significantly 
correlated with the scores of “agitation” and “anxiety-somatic” of the 
HDRS (“agitation”, correlation coefficient= -0.381, p= 0.005; “anxiety-
somatic”, correlation coefficient= -0.386, p= 0.005) in all 52 patients. 
There was also a significant correlation between the H/M ratio of the late 
phase and the scores of “agitation” and “anxiety-somatic” of the HDRS 
(“agitation”, correlation coefficient= -0.509, p= 0.002; “anxiety-somatic”, 
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correlation coefficient= -0.455, p= 0.006) in 35 patients who did not have 
clinical features of DLB (parkinsonism, visual hallucination, fluctuation of 
cognition, RBD) . 
Spearman’s correlation analysis between the H/M ratio of the late phase 
and composite scores of the HDRS revealed that the H/M ratio was 
significantly correlated with “somatic and psychic anxiety” (Marcos) 
(correlation coefficient= -0.425, p= 0.002) and “somatic 
anxiety/somatization factor” (Pancheri)(correlation coefficient= -0.341, p= 
0.013) in all 52 patients. There was also a significant correlation between 
the H/M ratio of the late phase and composite scores of the HDRS “somatic 
and psychic anxiety” (Marcos) (correlation coefficient= -0.497, p= 0.002) 
in 35 patients who did not have clinical features of DLB. 
   There were no significant differences between low and normal uptake 
groups in the total and item scores of the HDRS (Table 2). As to HDRS 
composite scores, mean scores of “somatic and psychic anxiety” (Marcos), 
“somatic anxiety/somatization factor” (Pancheri), and “pure depressive 
dimension” (Pancheri) in the low uptake group were higher than those in 
the normal uptake group (Table 2).   
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   There was no significant difference between mean GAF scores at 
admission of low and normal uptake groups, but improvement of GAF 
scores of the low uptake group were lower than those of the normal uptake 
group (Table 1). 
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DISCUSSION 
During the investigation period, 83 elderly patients with major depression 
entered the psychiatric ward. Of the 83 patients, 52 underwent MIBG 
scintigraphy, and 14 patients showed low MIBG uptake. Therefore, 26.9% 
(14/52) of the patients who took the examination and at least 16.9% (14/83) 
of the elderly inpatients with depression showed a low MIBG uptake. An 
autopsy study of 124 elderly people who did not have dementia reported 
that brainstem Lewy bodies were associated with late-life depressive 
symptoms, and that in a subscore analysis of depressive symptoms were 
associated with somatic symptoms. 25 In another study of 36 autopsy brains 
with a history of depression, at least four brains (11.1%) showed moderate 
or severe Lewy body pathology in the substantia nigra or locus ceruleus.26 
Of 9 patients with depression who developed the first episode after the age 
of 60, four subjects (44%) received the neuropathological diagnosis of 
DLB.27 In a clinical setting, of consecutive 167 inpatients over 50 years of 
age with mood disorder, 23 subjects (13.8%) were finally diagnosed with 
DLB.12 Moreover, while the sensitivity of the MIBG test to detect DLB is 
moderate, the specificity is very high.15 Therefore, there may have been 
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some persons with LBD in the normal uptake group. Considering our study 
and these past reports together, it is possible that more than 10% of aged 
patients with major depression may suffer from Lewy body pathology. In 
elderly patients with depression, there are many cases that it is difficult to 
distinguish them from dementia and mild cognitive impairment, and there 
is a possibility that this study may include MCI patients with DLB 
pathology.      
   Lewy body pathology is not rare in aged people. However, according to 
a community-based autopsy study in Japan, the frequency of Lewy body 
pathology including incidental Lewy bodies in the brain is 0% in the sixties 
and 10–15% in the seventies.27 In this study, if the subjects are limited to 
those in their sixties, of 34 patients with major depression, 20 underwent 
MIBG scintigraphy, and five patients showed low MIBG uptake. Therefore, 
25.0% (5/20) of the patients who took the examination and at least 14.7% 
(5/34) of the elderly in-patients with depression showed low MIBG uptake. 
Therefore, the proportion of elderly depressed patients with low MIBG 
intake is higher than that of the general population, and that the proportion 
of people with Lewy body pathology is also higher than the general 
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population. 
   A significant relationship was found between the H/M ratio of MIBG 
and several HDRS item scores by correlation analysis in this study. The 
lower the H/M ratio was, the higher the scores of agitation, somatic anxiety, 
and retardation were. Further, the scores of “somatic and psychic anxiety 
(Marcos)” and “somatic anxiety/somatization factor (Pancheri)” increased 
as the H/M ratio decreased.  
   Among patients with depression and DLB, some of the patients who 
were diagnosed with mood disorder at admission and who were thereafter 
diagnosed with DLB at discharge were previously reported to show severe 
agitation.12 In another report on the comparison between PD patients with 
depression and non-PD patients with depression, inner restlessness and 
irritability was more common in PD patients with depression than in non-
PD patients with depression, whereas a higher proportion of non-PD 
patients with depression had attempted suicide, experienced delusions, and 
exhibited a flattening of affect compared to PD patients with 
depression.29,30 Therefore, it is not strange that depressive patients with low 
cardiac MIBG uptake showed severer agitation than those with normal 
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cardiac MIBG uptake in this study.  
   Anxiety and apathy are very common in Parkinson disease. The pooled 
prevalence of anxiety in patients with PD was 30.1%.31 A higher depression 
score was associated with severer persistent anxiety in PD.32 In untreated 
early-stage PD, 19.0% of the patients were diagnosed as apathetic, and 
apathy was significantly associated with fatigue.33 In the diagnosis of DLB, 
anxiety and apathy are among the supportive clinical features.34 In elderly 
patients with depression, those who had somatic complaints such as fatigue 
may be more likely to have Lewy body pathology. 
   In PD, somatic scores on the anxiety scale were reported to be 
associated with autonomic failure.35 Orthostatic hypotension is closely 
associated with low cardiac MIBG uptake in DLB.36,37 Thus, low cardiac 
MIBG uptake may be closely related to anxiety in Lewy body disease. 
   Elderly patients with depression show similar remission rates compared 
to middle-aged patients with depression, but relapse rates appear to be 
higher. However, patients with Parkinson disease with major depression are 
reported to be less likely to experience remission.1,4 In this study, the GAF 
scores at discharge of the low cardiac MIBG uptake group were lower than 
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those of the normal cardiac MIBG uptake group. Some depressive patients 
with low cardiac MIBG uptake may show low therapeutic reactivity, 
similar to Parkinson disease patients with depression.  
   This study has several limitations. First, in this study, DAT-SPECT 
imaging was not performed. When this research was performed, health 
insurance in Japan did not cover DAT-SPECT. Therefore, we did not 
evaluate dopaminergic denervation and its relationship with symptoms. 
Second, needless to say, low cardiac MIBG uptake does not automatically 
indicate the presence of Lewy body disease. Third, this study included a 
relatively small number of patients. Therefore, this is an exploratory study, 
and further study including a larger number of patients is needed. Fourth, 
low MIBG uptake was reported to be associated with orthostatic 
hypotension. However, we did not evaluate orthostatic hypotension in this 
study. Fifth, RBD was not evaluated using an objective assessment method. 
Therefore, there are more possibilities for patients with potential RBD. 
Regardless of these shortcomings, this is the first report to show a 
significant relationship between the H/M ratio of the MIBG test to a few 
depressive symptoms in elderly patients with depression.  
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